Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth
Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth
1. Parenteral Nutrition Market to 2018 - Rising Incidence of
Chronic Diseases such as Cancer, AIDS and Gastrointestinal
(GI) Disorders, and Increased Use of Specialty Drugs Drive
Growth
Report Details:
Published:November 2012
No. of Pages: 70
Price: Single User License – US$3500
Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS
and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research,
“Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS
and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth”. It
provides in-depth analysis of the market size and drivers and barriers that affect the PN market.
The report analyzes the markets for parenteral nutrition in the US, the top five countries in Europe
(the UK, Germany, France, Italy and Spain) and Japan. Sales value is forecast until 2018 for key
geographies. Further, the report provides competitive benchmarking for the leading companies
and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global
markets.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GBI Research’s team of industry experts.
The PN market is rapidly growing with the increasing incidence of diseases such as cancer, AIDS
and GI disorders including short bowel syndrome, ischemic bowel disease, pseudo obstruction
and Crohn’s disease. The other major factor driving growth of the PN market is an increase in the
elderly population in the developed countries. In 2011, the global PN market was estimated to be
worth $2.9 billion, representing a CAGR of 6.3% between 2004 and 2011. The US market, with
sales worth $1,476m in 2011, accounted for 50.7% of the total PN market. The market in the top
five countries in Europe was estimated to be $1,275m, the second largest PN market, and to have
grown at a CAGR of 5.4% between 2004 and 2011. The PN market in Japan registered a share of
2. 5.4% of the total PN market, accounting for $157m sales value in 2011.
By 2018, the PN market is forecast to be worth $4,861m, representing a CAGR of 7.6% between
2011 and 2018. The US is expected to remain the largest segment in the PN market with $2,492m
of sales in 2018. The PN market in the top five countries in Europe will be the second largest
segment with $2,104m in revenues in 2018. Japan, which was the smallest segment in 2011, is
expected to register sales value of $265m in 2018, indicating a CAGR of 7.8% between 2011 and
2018. The PN market M&A landscape demonstrated a fairly moderate level of activity between
2004 and 2010, with seven major acquisition deals signed during the time period.
Scope
- Annualized market data for the PN market from 2004 to 2011, forecast forward to 2018.
- Analysis of the PN market in the leading geographies of the world, which include the US, the top
five countries in Europe (the UK, Germany, France, Italy, Spain) and Japan.
- Market segmentation of the PN market which includes the amino acid, lipids, carbohydrates and
additives market in the leading geographies.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of the leading companies. The key companies studied in this report
are Baxter, B. Braun, Fresenius Kabi, Hospira, Otsuka Pharmaceutical Factory, Terumo
Corporation and Ajinomoto.
- Key M&A activities, licensing agreements that have taken place between 2004 and 2011 in the
global PN market.
Reasons to buy
- Develop market-entry and market expansion strategies by identifying the leading geographic
markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class
products with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio
gaps.
Get your copy of this report @
http://www.reportsnreports.com/reports/206061-parenteral-nutrition-market-to-2018-rising-incidence-of-chronic-
diseases-such-as-cancer-aids-and-gastrointestinal-gi-disorders-and-increased-use-of-specialty-drugs-drive-
growth.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
3. 2 Parenteral Nutrition Market to 2018 - Introduction 9
3 Parenteral Nutrition Market to 2018 - Overview 10
3.1 Clinical Nutrition 10
3.1.1 Enteral Nutrition 11
3.1.2 Parenteral Nutrition 11
4 Parenteral Nutrition Market to 2018 - Market Characterization and Forecasts 15
4.1 Revenue Forecasts 15
4.2 Parenteral Nutrition Market Drivers 16
4.2.1 Increase in the Incidence of Diseases such as Cancer, AIDS and GI Disorders that Require
Nutrition Support 17
4.2.2 Increase in the Elderly Population will Drive PN Market Growth 17
4.2.3 The Home Parenteral Nutrition Sector will Witness Strong Market Growth 17
4.3 Parenteral Nutrition Market Restraints 17
4.3.1 Reimbursement Regulations will Hinder Market Growth in the US 17
4.3.2 Increasing Preference for Enteral Nutrition will Restrain Market Growth 17
4.3.3 Increasing Preference for Multi-chamber Bags Decreases Cost of Therapy 18
5 Parenteral Nutrition Market to 2018 - Geographical Landscape 19
5.1 Revenues by Geographical Segmentation 19
5.2 The US 21
5.2.1 Sales Value 21
5.2.2 Nutrient Market Segmentation 22
5.2.3 Key Products 22
5.3 Top Five Countries in Europe 23
5.3.1 Sales Value 23
5.3.2 Nutrient Market Segmentation 24
5.3.3 Key Products 24
5.4 Japan 25
5.4.1 Sales Value 25
5.4.2 Nutrient Market Segmentation 26
5.4.3 Key Products 26
6 Parenteral Nutrition Market to 2018 - Nutrient Market Segmentation 27
6.1 Overview 27
6.2 Amino Acids Market 28
6.2.1 Global Sales Value 28
6.2.2 Sales Value by Geography 28
6.3 Lipids Market 29
6.3.1 Global Sales Value 29
6.3.2 Sales Value by Geography 29
6.4 Carbohydrates Market 30
6.4.1 Global Sales Value 30
6.4.2 Sales Value by Geography 30
6.5 Additives Market 31
4. 6.5.1 Global Sales Value 31
6.5.2 Sales Value by Geography 31
7 Parenteral Nutrition Market - Marketed Products 32
7.1 Baxter International Inc. 32
7.1.1 OLIMEL 32
7.1.2 Clinimix 33
7.1.3 ClinOleic 20% 34
7.1.4 Clinisol 15% 35
7.2 B. Braun Melsungen AG 36
7.2.1 NuTRIflex System 36
7.2.2 Lipofundin 37
7.2.3 Aminoplasmal 38
7.2.4 FreAmine III 39
7.3 Fresenius Kabi AG 40
7.3.1 Intralipid 40
7.3.2 SmofKabiven 41
7.3.3 Dipeptiven 42
7.3.4 Omegaven 43
7.4 Hospira, Inc. 44
7.4.1 Aminosyn 44
7.4.2 Liposyn 46
7.5 Otsuka Pharmaceutical Factory Inc. 47
7.5.1 Elneopa 47
7.5.2 Neoparen 47
7.5.3 B-Fluid 48
7.6 Terumo Corporation 49
7.6.1 Unicaliq 49
7.6.2 Fulcaliq 50
8 Parenteral Nutrition Market to 2018 - Competitive Landscape 51
8.1 Market Share Analysis: Parenteral Nutrition 51
8.2 Competitive Profiling 52
8.2.1 Baxter International Inc. 52
8.2.2 B. Braun Melsungen AG 54
8.2.3 Fresenius Kabi AG 56
8.2.4 Hospira, Inc. 58
8.2.5 Otsuka Pharmaceutical Factory Inc. 60
8.2.6 Terumo Corporation 61
9 Parenteral Nutrition Market to 2018 - Strategic Consolidations 62
9.1 Overview 62
9.2 Major Acquisitions in the Parenteral Nutrition Market 63
9.2.1 Baxter International Completes Acquisition of Prism Pharma for $338m in April 2011 63
9.2.2 Baxter Acquires Willow Healthcare Services in July 2009 63
5. 9.2.3 Fresenius Acquires Novartis Nutrition and Nestle Espana in December 2007 63
9.2.4 Fresenius Kabi Acquires Infusia A.S. in December 2004 63
9.2.5 Fresenius Kabi Acquires Clinico GmbH in October 2005 63
9.2.6 Fresenius Kabi Acquires Isotec Nutrition from Alliance Pharmaceuticals in May 2004 63
9.2.7 Hospira Acquires Clayton Manufacturing Facility from Fresenius Kabi in June 2004 63
9.3 Major Agreements in the Parenteral Nutrition Market 64
9.3.1 Baxter Signs Agreement with Hanmi Pharmaceuticals in December 2010 64
9.3.2 Hospira Signs a Five-year Agreement with Novation in October 2010 64
9.3.3 B. Braun Signs Agreement with Amerinet Inc in October 2009 64
9.3.4 B. Braun Signs Agreement with Premier Purchasing Partners in August 2008 64
9.3.5 Hospira Announces New Contract with Premier Purchasing Partners in August 2008 65
9.3.6 Hospira Announces New Contract with HealthTrust Purchasing Group in February 2008 65
9.3.7 Baxter and Novation Sign Two-year Contract Extension in October 2007 65
9.3.8 Baxter Announces Plans to Form Parenteral Nutrition Joint Venture with Baiyunshan in
China in August 2007 65
9.3.9 B. Braun Signs Agreement with Curlin Medical in March 2006 65
9.3.10 Fresenius Kabi and Pharmatel Pty Ltd. Formed a Joint Venture in September 2004 66
10 Parenteral Nutrition Market to 2018 - Appendix 67
10.1 Market Definitions 67
10.2 Abbreviations 67
10.3 Bibliography 68
10.4 Research Methodology 69
10.4.1 Coverage 69
10.4.2 Secondary Research 69
10.4.3 Primary Research 69
10.4.4 Section Methodology 70
10.4.5 Expert Panel Validation 70
10.5 Contact Us 70
10.6 Disclaimer 70
1.1 List of Tables
Table 1: Parenteral Nutrition Market, Global, Nutritional Status Assessment, 2011 10
Table 2: Parenteral Nutrition Market, The US, A.S.P.E.N. Guidelines for Parenteral Nutrition, 2004
13
Table 3: Parenteral Nutrition Market, Global, Revenues ($m), 2004-2011 15
Table 4: Parenteral Nutrition Market, Global, Revenue Forecasts ($m), 2011-2018 15
Table 5: Parenteral Nutrition Market, Global, Revenue by Geographical Segmentation ($m), 2004-
2011 19
Table 6: Parenteral Nutrition Market, Global, Revenue Forecasts by Geographical Segmentation
($m), 2011-2018 20
Table 7: Parenteral Nutrition Market, The US, Revenues ($m), 2004-2011 21
Table 8: Parenteral Nutrition Market, The US, Revenue Forecasts ($m), 2011-2018 21